Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ex vivo expanded human autologous regulatory T cells (Nanjing Drum Tower Hospital)
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy involves the isolation, ex vivo expansion, and subsequent autologous transplantation of regulatory T cells (Tregs) into patients with type 1 diabetes mellitus (T1DM). Developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, the therapy aims to address the functional deficiency of Tregs observed in T1DM patients. By increasing the number of functional Tregs, the treatment seeks to restore immune tolerance to pancreatic islets and halt the autoimmune destruction of insulin-producing beta cells. The therapy is currently undergoing Phase 1 clinical evaluation to assess its safety and therapeutic potential.
- Other names
- Autologous regulatory T cellsAutologous TregsEx vivo Expanded Human Autologous Regulatory T Cells
02
Targets
MHC II (Major histocompatibility complex class II receptor)Neuraminidase
Beyond the preview
Go deeper on ex vivo expanded human autologous regulatory T cells (Nanjing Drum Tower Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ex vivo expanded human autologous regulatory T cells (Nanjing Drum Tower Hospital).